diabetes
Type 3 diabetes more common than Type 1 and often misdiagnosed
October 25, 2017Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
In the first ever study of its kind, researchers from the University of Surrey examined the records of more than …
Novo’s diabetes treatment semaglutide gets unanimous FDA backing
October 19, 2017Sales and Marketing Novo Nordisk, diabetes, semaglutide
Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one …
Sanofi plans summit to tackle diabetes in 5 million Nigerian citizens
October 17, 2017Manufacturing and Production, Medical Communications Nigeria, Sanofi, WHO, diabetes, pharma
Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million …
J&J exits insulin pump business, rival looks to scoop patients
October 10, 2017Manufacturing and Production Johnson & Johnson, biotech, diabetes, drugs, pharma, pharmaceutical
Johnson & Johnson’s Animas Corporation will cease business and close operations after the pharma giant could not find a buyer …
Sanofi promotes global head of diabetes to expand role
October 6, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, biotech, diabetes, drugs, pharma, pharmaceutical
Sanofi has promoted Stefan Oelrich to the position of Executive Vice President of Diabetes and Cardiovascular (DCV), giving him a …
Novo’s Xultophy beats basal insulin in cutting cardiovascular risk
September 14, 2017Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million
September 6, 2017Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical
Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …
Novo diabetes drug outperforms Lilly rival at Phase 3
August 17, 2017Research and Development Eli Lilly, Novo Nordisk, diabetes, life sciences, medicine, pharma, pharmaceutical, type 2 diabetes
Novo Nordisk has revealed that its diabetes drug semaglutide managed to outperform Eli Lilly’s own treatment dulaglutide (Trulicity) in controlling …
Less sleep in children linked to increased risk of diabetes
August 16, 2017Research and Development biotech, diabetes, drugs, pharma, pharmaceutical, type 2, type-2
A study emerging from St George’s University of London found that children who slept an hour less than the recommended …
‘Hugely disturbing’ rise in UK children with type 2 diabetes, report finds
August 14, 2017Medical Communications, Sales and Marketing childhood obesity, diabetes, healthcare, life sciences, obesity, pharma, pharmaceuticals
A report from the Royal College of Paediatrics and Child Health (RCPCH) has highlighted a “hugely disturbing” rise in cases …
Top Ten most popular articles on Pharmafile.com this week
August 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Merck, NICE, Parkinson's, biotech, diabetes, pharma, pharmaceutical, top ten
Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …
Pioneering immunotherapy halts progression of type 1 diabetes
August 10, 2017Research and Development Type 1 diabetes, diabetes, drugs, insulin, life sciences, medicines, pharma, pharmaceutical
In a first for the disease area, an immunotherapy treatment for diabetes, developed by researchers at King’s College London and …
Diabetes drug holds promise to slow Parkinson’s progression
August 4, 2017Medical Communications, Research and Development Parkinson's disease, biotech, diabetes, drugs, pharma, pharmaceutical
There are currently no treatments that are able to slow the development of Parkinson’s disease. This unmet medical need will …
Revealing the missing evidence: Randomised real-life studies in basal insulin therapy
July 10, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, diabetes, real world data
Sanofi’s Riccardo Perfetti, Head of Global Diabetes, and Jukka Westerbacka, Medical Director, Global Medical Affairs, discuss how the significance of …
‘Vaccine’ to lower cholesterol enters human trials
June 20, 2017Manufacturing and Production, Research and Development AFFiRis, cholesterol, diabetes
After positive results for a ‘vaccine’ to combat fatty deposits in the arteries in mice, the researchers have taken the …
